{"id":{"repo_id":"dominican","oai_identifier":"oai:scholar.dominican.edu:masters-theses-1351"},"canonical_url":"https://search.dev.ndltd.org/etd/dominican/oai:scholar.dominican.edu:masters-theses-1351","repository":{"repo_id":"dominican","name":"Dominican University of California","base_url":"https://scholar.dominican.edu/do/oai/"},"display":{"title":"Combinational Therapy to Mitigate α-Dicarbonyl Toxicity","abstract":"<p>Diabetes mellitus is a metabolic disease characterized by hyperglycemia that affects 30 million children and adults in the United States alone. Patients suffering from diabetes have high concentrations of reactive α-dicarbonyls (α-DCs) like, methylglyoxal (MGO). The abundance of α-DCs form advanced glycation end products (AGEs); in turn, the accumulation of AGEs has been linked to secondary complications. Secondary complications include diabetic neuropathy, nephropathy and cardiomyopathy. A recently discovered TRPA-1-Nrf-2 pathway is a conserved mechanism in vertebrates and invertebrates that detoxifies α-DCs; however, regulators that activate the detoxification mechanism are currently unknown. Several supplement grade compounds were screened for TRPA-1-Nrf2 induced activity in <em>Caenorhabditis elegans</em>. The drug screen revealed several candidates that decreased methylglyoxal levels using the TRPA-1-Nrf-2 pathway. Regulatory mechanisms that trigger this detoxification pathway open up avenues for therapeutic studies. Candidates were utilized to determine their therapeutic efficacy in mammalian <em>in vitro</em> studies, in the background of methylglyoxal stress. In this work, we pursue combinational therapy to identify a more effective approach at mitigating neurotoxicity. We show that a five-compound combination ameliorates methylglyoxal stress in multiple dopaminergic cell lines: N27, PC12 and SH-SY5Y. Results indicate that combinational therapy counteracts methylglyoxal stress more effectively than compounds used in isolation. Data suggests that the five-compound mixture can be used as a potential supplement to treat diabetic complications in patients suffering from long term diabetes.</p>","abstract_html":"&lt;p&gt;Diabetes mellitus is a metabolic disease characterized by hyperglycemia that affects 30 million children and adults in the United States alone. Patients suffering from diabetes have high concentrations of reactive α-dicarbonyls (α-DCs) like, methylglyoxal (MGO). The abundance of α-DCs form advanced glycation end products (AGEs); in turn, the accumulation of AGEs has been linked to secondary complications. Secondary complications include diabetic neuropathy, nephropathy and cardiomyopathy. A recently discovered TRPA-1-Nrf-2 pathway is a conserved mechanism in vertebrates and invertebrates that detoxifies α-DCs; however, regulators that activate the detoxification mechanism are currently unknown. Several supplement grade compounds were screened for TRPA-1-Nrf2 induced activity in &lt;em&gt;Caenorhabditis elegans&lt;/em&gt;. The drug screen revealed several candidates that decreased methylglyoxal levels using the TRPA-1-Nrf-2 pathway. Regulatory mechanisms that trigger this detoxification pathway open up avenues for therapeutic studies. Candidates were utilized to determine their therapeutic efficacy in mammalian &lt;em&gt;in vitro&lt;/em&gt; studies, in the background of methylglyoxal stress. In this work, we pursue combinational therapy to identify a more effective approach at mitigating neurotoxicity. We show that a five-compound combination ameliorates methylglyoxal stress in multiple dopaminergic cell lines: N27, PC12 and SH-SY5Y. Results indicate that combinational therapy counteracts methylglyoxal stress more effectively than compounds used in isolation. Data suggests that the five-compound mixture can be used as a potential supplement to treat diabetic complications in patients suffering from long term diabetes.&lt;/p&gt;","abstract_has_math":false,"creators":["Ramirez, Jessica"],"institution":null,"degree_name":"Master of Science","degree_level":"Master's Thesis","degree_discipline":"Biological Sciences","degree_department":null,"school":null,"contributors":["Pankah Kapahi, PhD","Kiowa Bower, PhD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-05-01T07:00:00Z","date_published":"2018-05-01T07:00:00Z","updated_at":"2026-07-24T02:04:51Z","subjects":["Hyperglycemia","Diabetes","Medicine and Health Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://scholar.dominican.edu/masters-theses/336","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Pankah Kapahi, PhD","Kiowa Bower, PhD"]},{"key":"dc:creator","label":"Author","values":["Ramirez, Jessica"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2023-05-31T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biological Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Master's Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Hyperglycemia","Diabetes","Medicine and Health Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://scholar.dominican.edu/masters-theses/336"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>Diabetes mellitus is a metabolic disease characterized by hyperglycemia that affects 30 million children and adults in the United States alone. Patients suffering from diabetes have high concentrations of reactive α-dicarbonyls (α-DCs) like, methylglyoxal (MGO). The abundance of α-DCs form advanced glycation end products (AGEs); in turn, the accumulation of AGEs has been linked to secondary complications. Secondary complications include diabetic neuropathy, nephropathy and cardiomyopathy. A recently discovered TRPA-1-Nrf-2 pathway is a conserved mechanism in vertebrates and invertebrates that detoxifies α-DCs; however, regulators that activate the detoxification mechanism are currently unknown. Several supplement grade compounds were screened for TRPA-1-Nrf2 induced activity in <em>Caenorhabditis elegans</em>. The drug screen revealed several candidates that decreased methylglyoxal levels using the TRPA-1-Nrf-2 pathway. Regulatory mechanisms that trigger this detoxification pathway open up avenues for therapeutic studies. Candidates were utilized to determine their therapeutic efficacy in mammalian <em>in vitro</em> studies, in the background of methylglyoxal stress. In this work, we pursue combinational therapy to identify a more effective approach at mitigating neurotoxicity. We show that a five-compound combination ameliorates methylglyoxal stress in multiple dopaminergic cell lines: N27, PC12 and SH-SY5Y. Results indicate that combinational therapy counteracts methylglyoxal stress more effectively than compounds used in isolation. Data suggests that the five-compound mixture can be used as a potential supplement to treat diabetic complications in patients suffering from long term diabetes.</p>"]},{"key":"dc:title","label":"Title","values":["Combinational Therapy to Mitigate α-Dicarbonyl Toxicity"]}]}],"canonical_facts":{"dc:contributor":["Pankah Kapahi, PhD","Kiowa Bower, PhD"],"dc:creator":["Ramirez, Jessica"],"dc:date.available":["2023-05-31T07:00:00Z"],"dc:description.abstract":["<p>Diabetes mellitus is a metabolic disease characterized by hyperglycemia that affects 30 million children and adults in the United States alone. Patients suffering from diabetes have high concentrations of reactive α-dicarbonyls (α-DCs) like, methylglyoxal (MGO). The abundance of α-DCs form advanced glycation end products (AGEs); in turn, the accumulation of AGEs has been linked to secondary complications. Secondary complications include diabetic neuropathy, nephropathy and cardiomyopathy. A recently discovered TRPA-1-Nrf-2 pathway is a conserved mechanism in vertebrates and invertebrates that detoxifies α-DCs; however, regulators that activate the detoxification mechanism are currently unknown. Several supplement grade compounds were screened for TRPA-1-Nrf2 induced activity in <em>Caenorhabditis elegans</em>. The drug screen revealed several candidates that decreased methylglyoxal levels using the TRPA-1-Nrf-2 pathway. Regulatory mechanisms that trigger this detoxification pathway open up avenues for therapeutic studies. Candidates were utilized to determine their therapeutic efficacy in mammalian <em>in vitro</em> studies, in the background of methylglyoxal stress. In this work, we pursue combinational therapy to identify a more effective approach at mitigating neurotoxicity. We show that a five-compound combination ameliorates methylglyoxal stress in multiple dopaminergic cell lines: N27, PC12 and SH-SY5Y. Results indicate that combinational therapy counteracts methylglyoxal stress more effectively than compounds used in isolation. Data suggests that the five-compound mixture can be used as a potential supplement to treat diabetic complications in patients suffering from long term diabetes.</p>"],"dc:identifier":["https://scholar.dominican.edu/masters-theses/336"],"dc:subject":["Hyperglycemia","Diabetes","Medicine and Health Sciences"],"dc:title":["Combinational Therapy to Mitigate α-Dicarbonyl Toxicity"],"thesis:degree_discipline":["Biological Sciences"],"thesis:degree_level":["Master's Thesis"],"thesis:degree_name":["Master of Science"]},"updated_at":"2026-07-24T02:04:51Z"}